Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez-Otero

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Blood Neoplasia|April 24, 2026
Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myelomaLorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal GammopathiesLeire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, et al.
Nature Medicine|March 17, 2023
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myelomaMarta Larrayoz, Maria J Garcia-Barchino, Jon Celay, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Blood Neoplasia|April 24, 2026
Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myelomaLorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal GammopathiesLeire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, et al.
Nature Medicine|March 17, 2023
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myelomaMarta Larrayoz, Maria J Garcia-Barchino, Jon Celay, et al.
Blood|January 29, 2026
Immune biomarkers of increased infection risk in multiple myelomaAintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, et al.
Pageof 8